TRK Inhibitor Monohydrate Formulation for Stable Extended Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine, particularly the anhydrate form, face issues with instability and rapid aqueous dissolution, leading to challenges in formulation and polymorphic conversion during storage and processing.
Innovation Solution
The development of a monohydrate form of 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine, which exhibits improved physical stability and slower dissolution, addressing the formulation challenges of the anhydrate form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the anhydrate form of the Trk inhibitor is used in formulation, then the formulation can be prepared, but the compound exhibits rapid aqueous dissolution and polymorphic conversion during storage
Solution Approach 1:
The patent applies parameter changes by transforming the compound from its anhydrate form to a monohydrate crystalline form. This structural parameter change (adding water of crystallization) fundamentally alters the physical properties, resulting in slower aqueous dissolution rates and improved stability during storage while maintaining the desired therapeutic effect.
2Reliability
If the anhydrate form of the Trk inhibitor is used, then the formulation can be prepared, but polymorphic conversion occurs during storage and processing
Solution Approach 1:
The patent resolves polymorphic instability by changing the crystalline structure parameter from anhydrate to monohydrate form. This structural transformation creates a more stable polymorph that resists conversion during storage and processing, ensuring consistent formulation performance and reliability.
3Duration of action of moving object
If extended release formulations are desired, then treatment duration is improved, but formulation complexity increases
Solution Approach 1:
The patent achieves extended release functionality by changing the dissolution rate parameter through crystalline form modification. The monohydrate form's inherently slower dissolution kinetics provide extended release properties without requiring complex delivery systems, thereby reducing formulation complexity while maintaining prolonged treatment duration.
Data Source
AI summary
Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5b-]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.